Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | VEGFA | P15692 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598891 | 0.85 | HTR6 (0.55) | MMP2MMP9L3MBTL1POLBHTT | |
| SCHEMBL17340664 | 0.78 | RAPGEF4 (0.54) | MMP2RAPGEF4CA1CA2VEGFA | |
| SCHEMBL3834757 | 0.78 | RAPGEF4 (0.65) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL27717816 | 0.77 | RAPGEF4 (0.52) | MMP2MMP9RAPGEF4CA1CA2 | |
| SCHEMBL23699019 | 0.75 | RAPGEF4 (0.61) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL29001261 | 0.75 | CA1 (0.59) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL5535689 | 0.75 | RAPGEF4 (0.61) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL7641128 | 0.75 | RAPGEF4 (0.61) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL1365792 | 0.75 | RAPGEF4 (0.61) | MMP2RAPGEF4CA1CA2L3MBTL1 | |
| SCHEMBL3188642 | 0.75 | RAPGEF4 (0.61) | MMP2RAPGEF4CA1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| EP-1558580-B1 | N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIAL AGENTS | PROCTER & GAMBLE (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1558580-B1 | N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIAL AGENTS | PROCTER & GAMBLE (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7247632-B2 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247632-B2 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247632-B2 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050256126-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-17 | — | — | US | disclosed |
| US-6946479-B2 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC | 2004-05-20 | — | — | US | disclosed |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC | 2004-05-20 | — | — | US | disclosed |
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | WARNER CHILCOTT COMPANY, LLC | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097559-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, TLR1, CYP51A1 | MMP2 1737/4885MMP9 3433/4885RAPGEF4 4110/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | MMP2 771/4885MMP9 2972/4885RAPGEF4 2141/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | MMP2 771/4885MMP9 2972/4885RAPGEF4 2141/4885 |
| US-20050256126-A1 | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, TLR6 | MMP2 1389/4885MMP9 3474/4885RAPGEF4 3888/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | MMP2 771/4885MMP9 2972/4885RAPGEF4 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.